


Supplemental Figure 2: Anti-tumor activity of 5F11-28Z versus HRS3-28Z



Supplemental Figure 2. Comparison of anti-tumor activity of T cells transduced with MSGV1-5F11-28Z versus T cells transduced with MSGV1-HRS3-28Z. Tumors were established in NSG mice by intradermal injection of HH cells. When palpable tumors were present, mice received infusions of T cells that were either untransduced or transduced with one of the indicated CARs. The 5F11-28Z and HRS3-28Z CARs were the same except for having different scFvs. MSGV1-SP6-CD828Z-transduced T cells were included as a negative control. (A) Tumor volumes (mean \pm SEM) for the different groups are shown. The graphs show the combined results of 2 experiments of 5 mice per experiment, so n=10 for each group. Day 0 was the day of intravenous infusions of 6×10^6 T cells expressing the indicated CARs. Tumor size curves end when the 1st mouse of a group died. At day 21, there was a statistically significant difference in tumor size between MSGV1-5F11-28Z and MSGV1-HRS3-28Z; $P=0.0014$ by 2-tailed Mann-Whitney test. (B) Kaplan-Meier survival plots of the same mice as in A are shown. There was a statistically significant difference ($P<0.0001$) for the comparison of T cells transduced with either MSGV1-5F11-28Z or MSGV1-HRS3-28Z versus MSGV1-SP6-CD828Z. There was not a statistically significant difference ($P=0.067$) when survival of mice receiving T cells transduced with MSGV1-5F11-28Z versus MSGV1-HRS3-28Z were compared. Survival comparisons were made by log-rank test. $P<0.05$ was considered statistically significant.